Â鶹ӳ»­

Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors One patient experienced a complete response, and one patient had a partial response This type of cancer has limited treatment options, and most patients have a poor prognosis of six months or less AIC100 is a CAR T cell therapy that targets the ICAM-1 protein...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations  In this combination trial patients were matched by genetic features, not tumor type – a tumor-agnostic, molecularly matched trial that included 30 different cancer types  Prior studies indicated potential for synergy between these two therapies, and this study verified this in...